Science Corner – Cytonics Corporation

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

Science Corner, Our StoryJanuary 20, 20261KViews 0Likes 0Comments

Most people talk about lifespan. We obsess over how long we live. What actually matters is healthspan. How long we stay strong, mobile, and pain-free. Living to 90 means very little if your joints fail you at 60. At Cytonics Corporation, our mission is simple: extend healthspan by protecting the biology that makes movement…

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

Science Corner, Investor Relations, Our StoryJanuary 6, 20261KViews 0Likes 0Comments

You may have seen the recent headlines regarding a breakthrough in "anti-aging injections" for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in joints). While the media is…

#61 🛑 Can We Stop Osteoarthritis Before It Starts?

Science CornerDecember 20, 2025910Views 0Likes 0Comments

Some individuals inherit a genetic risk for osteoarthritis, potentially experiencing severe symptoms by their 40s or 50s. Early identification and treatment with alpha-2-macroglobulin (A2M) may preserve joint health and enhance quality of life. Development of CYT-108 aims to target the root cause of osteoarthritis, rather than just alleviate pain.

#60 👎 Where Big Pharma Tried And Failed

Science CornerNovember 4, 20251KViews 0Likes 0Comments

Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

#60 👎 Where Big Pharma Tried And Failed

Science CornerNovember 4, 20251KViews 0Likes 0Comments

Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

#55 🧬 Perfecting Nature’s Blueprint

Science CornerJuly 1, 20251KViews 0Likes 0Comments

Cytonics has developed CYT-108, a refined version of the naturally occurring protein Alpha-2-Macroglobulin (A2M), to combat osteoarthritis. By optimizing A2M for enhanced protease inhibition, the precision-engineered biologic minimizes side effects and maximizes therapeutic potential. It’s backed by extensive scientific validation and patented for patient safety and efficacy.

#54 🌿 The Beauty of Nature’s Design

Science CornerJune 26, 20251KViews 0Likes 0Comments

Cytonics is developing innovative therapies for osteoarthritis by leveraging Alpha-2-Macroglobulin (A2M), a natural protein that combats harmful enzymes. The initial success of their device, APIC™, led to the creation of CYT-108, a more potent and consistent engineered version of A2M, aimed at addressing the root causes of cartilage degradation.

#53 🧪 The Experiment That Started It All

Our Story, Science CornerJune 25, 20251KViews 0Likes 0Comments

The journey of developing a cartilage-protecting therapy began with a hypothesis about the A2M protein’s potential. Initial experiments showed A2M could significantly reduce cartilage destruction caused by osteoarthritis. This led to the creation of APIC™ and the more advanced CYT-108, which demonstrated remarkable efficacy in preclinical trials, paving the way for human clinical trials.

#45 🚨 Major Phase 1 Study Milestone Achieved!

Science Corner, Investor Relations, Our StoryJanuary 17, 20252KViews 0Likes 0Comments

The first nine patients have completed the Phase 1 clinical trial of CYT-108, with no reported adverse events. This biologic therapy aims to treat osteoarthritis by targeting cartilage-degrading enzymes. The company plans to initiate Phase 2 trials and will launch an equity crowdfunding campaign to finance further development.

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

#61 🛑 Can We Stop Osteoarthritis Before It Starts?

#60 👎 Where Big Pharma Tried And Failed

#60 👎 Where Big Pharma Tried And Failed

#55 🧬 Perfecting Nature’s Blueprint

#54 🌿 The Beauty of Nature’s Design

#53 🧪 The Experiment That Started It All

#45 🚨 Major Phase 1 Study Milestone Achieved!

Get fresh updates

Download Exclusive Investor Presentation & Stay Updated